Tech Company Financing Transactions
LifeMine Therapeutics Funding Round
On 8/6/2026, LifeMine Therapeutics secured $188 million in Series E financing from Milky Way Ventures, Arch Venture Partners and Bezos Expeditions.
Transaction Overview
Company Name
Announced On
8/6/2026
Transaction Type
Venture Equity
Amount
$188,000,000
Round
Series E
Investors
Milky Way Ventures (Lead Investor)
GV (Krishna Yeshwant)
Proceeds Purpose
LifeMine plans to use the proceeds to advance LIFE-001, including a planned Phase 2 kidney transplant study and a Phase 1b islet cell transplant study.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Acorn Park Dr.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
LifeMine is the first company to massively scale the genomic discovery of powerful new drug modalities from eukaryotic microbes. Our integrated, genomically-enabled drug discovery engine is poised to deliver a pipeline of medicines that will conquer previously unconquerable human diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Richard Klausner
Chief Executive Officer
Gregory Verdine
Chief Operating Officer
WeiQing Zhou
Vice President
Paola Castaldi
Vice President
Jared Cumming
Vice President
Thomas Ramseier
Vice President
Dawn Thompson
VP - Bus. Development
Iain McFadyen
VP - Bus. Development
Susanne Saalau
VP - Finance
Karen Guarco
Browse more venture capital transactions:
Prev: 8/6/2026: Factbird venture capital transaction
Next: 8/6/2026: Inevitable AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs